BioSpace News Archive

Partner Therapeutics, Inc. (PTx) announced publication of a single institution retrospective cohort review of 15 patients with pediatric malignancies and invasive fungal diseases that were refractory to antifungal therapy and treated adjunctively with Leukine (sargramostim; yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]).

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of inducement awards to Ricardo Fonseca, its new Vice President, Operations.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open on Thursday, January 5, 2023.

Veracyte, Inc. announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier were published in The Journal of Clinical Endocrinology & Metabolism.

Gritstone bio, Inc. announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference occurring January 9-12, 2023 in San Francisco.

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced the appointment of Robert Gagnon to its Board of Directors, effective December 13, 2022.

Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today the publication of data from its Phase 1b clinical trial of emraclidine, a novel muscarinic M4 selective positive allosteric modulator, in adults living with schizophrenia in The Lancet.

Bionomics Limited, a clinical-stage biopharmaceutical company developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders with high unmet medical need, announced that it has appointed Spyridon “Spyros” Papapetropoulos, M.D. as President and Chief Executive Officer, effective 5 January 2023.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 GLOW clinical trial evaluating the efficacy and safety of zolbetuximab in combination with CAPOX (a combination chemotherapy regimen that includes capecitabine and oxaliplatin).

WuXi Biologics, a leading global Contract Research, Development and Manufacturing Organization, announced that its subsidiary WuXi Biologics Co., Ltd. has been removed from the Unverified List by the U.S. Department of Commerce, effective Dec. 16, 2022.